Author:
Scholl S. M.,Beuzeboc P.,Harris A. L.,Pierga J. Y.,Asselain B.,Palangié T.,Dorval T.,Jouve M.,Diéras V.,Pouillart P.
Publisher
Springer Berlin Heidelberg
Reference31 articles.
1. Allred CD, Clark GM, Tandon AK et al (1992) HET-2/neu in node-negative breast cancer. Prognostic significance of overexpression influenced by the presence of in-situ carcinoma. J Clin Oncol 10:599–605
2. Baselga J, Tripathy D, Mendelsohn J et al (1994) Ongoing phase II study of intravenous recombinant anti-p185 HER2 monoclonal antibody 4D5 (Mab 4D5) in patients with stage IV breast cancer overexpressing HER2. Breast Cancer Res Treat 32:8
3. Bonadonna G, Valagussa P, Brmabilla C et al (1998) primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93–100
4. Burrows F, Thorpe PE (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90:8996–9000
5. Cabrera T, Fernandez MA, Sierra A, Garrido A, Garrido F (1996) High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50:127–134
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献